ASTRAZENECA yesterday said 2017 would mark a "turning point" as it grapples to replace a raft of patents scheduled to run out during the year.
Fourth quarter revenues were down 13 per cent at $5.6bn (£4.5bn) with full-year revenues lower by seven per cent at $23bn.
While the results were broadly in line with market expectations, the firm is under increasing pressure in its core business as cheaper versions of drugs come onto the market.
Shares fell over one per cent in early t
RelSci News & Alerts gets you:
- 10 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
- Competitive business intelligence through daily data updates
- Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox